Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2025 16:30 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

MORRISTOWN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic...
January 22, 2025 08:00 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Announces $9.0 Million Public Offering

EDISON, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic...
December 16, 2024 07:26 ET | Source: Polaris Market Research & Consulting LLP

Non-Alcoholic Steatohepatitis Treatment Market Set for 28.0% CAGR Growth, Projected to Hit $90.97 Billion by 2034 |PMR

New York, USA, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Market Statistics The global non-alcoholic steatohepatitis treatment market size was USD 7.70 billion in 2024, estimated at USD 9.85 billion in...
July 22, 2024 08:00 ET | Source: Hepion Pharmaceuticals, Inc.

Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement

Pharma Two B Ltd. (“Pharma Two B”) has entered into a merger agreement with Hepion Pharmaceuticals, Inc. (“Hepion”) (Nasdaq: HEPA)Immediately upon completion of the merger, current Pharma Two B...
May 27, 2024 11:33 ET | Source: The Rosen Law Firm PA

NATIONALLY RANKED ROSEN LAW FIRM Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKRO

NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September...
March 06, 2024 08:30 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell

EDISON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of...
March 06, 2024 06:00 ET | Source: Research Nester

Non-Alcoholic Steatohepatitis Treatment Market revenue to reach USD 48.3 Billion by 2035, says Research Nester

New York , March 06, 2024 (GLOBE NEWSWIRE) -- The global non-alcoholic steatohepatitis treatment market size is predicted to expand at 18% CAGR between 2023 and 2035. The market is projected to...
December 06, 2023 08:05 ET | Source: Organovo, Inc.

Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results

SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and...
May 04, 2022 08:37 ET | Source: The Insight Partners

Non-Alcoholic Steatohepatitis (NASH) Market Worth $24.26Bn, Globally, by 2028 at 47.1% CAGR - Exclusive Report by The Insight Partners

New York, May 04, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Non-Alcoholic Steatohepatitis (NASH) Market Forecast to 2028 - COVID-19 Impact and Global Analysis...
February 09, 2022 05:06 ET | Source: Vantage Market Research

NASH (Non-Alcoholic Steatohepatitis) Market to Reach USD 21,879 Million by 2028 - Powered by Increasing Pharmaceutical R&D Expenditure and Escalating Obese Population- Vantage Market Research

WASHINGTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research’s recent analysis of the Global Non-Alcoholic Steatohepatitis (NASH) Market finds that growing demand for ideal NASH...

Next Page keyboard_arrow_right